Epstein Secrets

up America Foundation. Howard Men Mr. Pien most recently served as Chairman of the Board and CEO of Medarex, Inc. from 2007 to its acquisition by Bristol Myers Squibb Company in September 2009. Prior to that, he was a private consultant from 2006 to 2007. Prior to that he served as President and CEO of Chiron Corporation

r. Pien is also a director of Vanda Pharmaceuticals and ViroPharma Incorporated. DACART CAPITAL LLC EFTA_R1_01138848 EFTA02295574 References • Michael Eisenson - Charlesbank, Managing Partner • Alan Salzman - VantagePoint, Managing Partner ■ Kevin Hrusovsky - Perkin Elmer, President of Life Sciences & Technology ■ Dan

p America Foundation. Howard Pien Mr. Pien most recently served as Chairman of the Board and CEO of Medarex, Inc. from 2007 to its acquisition by Bristol Myers Squibb Company in September 2009. Prior to that, he was a private consultant from 2006 to 2007. Prior to that he served as President and CEO of Chiron Corporation

at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and ViroPharma Incorporated. DACAR 1 CAPIIAL LLC EFTA00506153 References • Michael Eisenson - Charlesbank, Managing Partner • Alan Salzman - VantagePoint, Managing Partner • Kevin Hrusovsky - Perkin Elmer, President of Life Sciences & Technology • Dan

p America Foundation. Howard Pien Mr. Pien most recently served as Chairman of the Board and CEO of Medarex, Inc. from 2007 to its acquisition by Bristol Myers Squibb Company in September 2009. Prior to that, he was a private consultant from 2006 to 2007. Prior to that he served as President and CEO of Chiron Corporation

1,000 million in net asset value while achieving +21% returns over the course of four years. DACAR T C. API IAL LIS.; EFTA00506200 References • Michael Eisenson - Charlesbank, Managing Partner • Alan Salzman - VantagePoint, Managing Partner • Alex Barkas - Prospect, Managing Partner • Kevin Hrusovsky - Caliper Life Scie